Patent Hemostasis With Vasoband Versus TR Band

NCT ID: NCT04002791

Last Updated: 2020-11-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

253 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-16

Study Completion Date

2019-10-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients referred for cardiac catheterization to be performed using transradial access, a randomized comparison will be performed with the primary endpoint of patency of radial artery at the time of application of hemostatic compression band. The single radial only TR-Band (Terumo, Japan) will be compared to the dual balloon Vasoband (Vasoinnovations, USA) capable of ipsilateral ulnar artery compression.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction:

TRA is increasing in utilization across the world due to its established benefits of reduction in access site complications, cost, and increase in patient comfort (1). The most common structural consequence of TRA is radial artery occlusion (RAO). It occurs in 2-10% of patients undergoing TRA (2). Several pharmacologic as well as non-pharmacologic practices have been associated with RAO. Maintaining a hardware profile smaller than the inner diameter of radial artery has been associated with better radial artery patency rates after the procedure (3). Use of unfractionated heparin and other parenteral anticoagulants administered during the procedure has also been associated with reduction in RAO, with a dose-dependent effect with better reduction with higher doses of heparin (4,5).

One of the most effective intervention for reduction of RAO is avoidance of flow cessation in radial artery during hemostatic compression (6). This technique, called "patent hemostasis", has been shown to unequivocally and sizably reduce the incidence of RAO. In patients with small diameter radial arteries as well as low blood pressures, the ability to achieve and maintain patent hemostasis has been observed to be lower than those otherwise. In view of the co-dominant nature of forearm arterial circulation, the radial and ulnar arteries are interdependent and compression of ipsilateral ulnar artery has been shown to increase flow as well as peak flow velocity in the radial artery (7). Ipsilateral ulnar artery compression during hemostatic compression of a punctured radial artery, has been shown to sizably and significantly reduce the incidence of RAO compared to patent hemostasis (8). Randomized and observational datasets utilizing this technique published so far have been using two devices to achieve radial and ulnar compression, with difficult ergonomics leading to frequent dislodgment of ulnar compression during the radial artery hemostatic process.

The investigators intend to study the comparative efficacy of the first dedicated dual compression device in achieving patent hemostasis compared to the current popular radial artery compression device.

Patients and Methods:

Patients referred for diagnostic cardiac catheterization using TRA will be screened. Those providing written informed consent, will be enrolled in the study. A transradial cardiac catheterization will be performed using the standard technique as described below.

Catheterization Technique:

After sterile preparation as well as local anesthetic infiltration, 5 French hydrophilic introducer sheath will be introduced in the radial artery using standard puncture technique (9). Once the introducer is in the radial artery lumen, 200 µg of nitroglycerin, 2.5 mg of verapamil and 5000 IU of unfractionated heparin will be administered intra-arterially. 5 French or lower profile hardware will be used as per operator discretion to complete the procedure.

Once the procedure is completed, the patient will be randomized to:

Group 1, which will include patients receiving hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied to achieve full hemostasis.

Group 2, will consist of patients who will receive Vaso-band (VasoInnovations, Inc, USA), applied according to instructions for use, with ulnar balloon inflated for the first 60 minutes of radial artery hemostatic compression, with the radial balloon inflated to obtain full hemostasis, after the sheath is removed.

Primary Study End-point: Radial artery patency at 0-15 minutes after application of radial artery hemostatic compression.

Monitoring of Patency:

The radial artery patency will be monitored immediately after application of the band using reverse Barbeau test in both groups, and patency will be re-evaluated at 15 minutes after band application, 30 minutes after band application, 60 minutes after band application, as well as upon removal of the band at 120 minutes.

If longer duration of application of pressure with the band is necessary in either group to achieve hemostasis, the bands will be applied for longer duration and the adequacy of hemostasis will be evaluated every 15 minutes after 120-minute duration and the band removed once adequately adequate hemostasis has been achieved.

Radial patency will be assessed at 60 minutes after the band is removed.

Baseline demographic as well as procedural data, pharmacologic data, as well as elaborately data will be collected on every patient.

Statistical Analysis Plan:

Categorical variables will be expressed as proportions, and differences between the two groups will be assessed using chi-square test, or Pearson test as deemed appropriate. Numeric variables will be assessed for normality of the distribution, and will be expressed as mean and standard deviation for normally distributed variables, and median as well as interquartile range for those without normal distribution. Parametric tests will be used to compare differences between the two groups for normally distributed numeric variables, and nonparametric tests will be used in those variables with a non-normal distribution. Multivariable analysis if necessary, will be performed using forward selection binary logistic regression for categorical dependent variable and linear regression for numeric variables. Received operative characteristic derived c-statistic will be used to assess the stability of the model.

Sample Size Calculation:

Based on the available literature, using the current standard of care TR band, patent hemostasis defined as patency of radial artery during hemostatic compression at 15 minutes into compression is achievable in 75% of patients undergoing TRA. The only published randomized trial using prophylactic ipsilateral ulnar artery compression during radial artery hemostatic compression has shown 96% achievement of patent hemostasis at 15 minutes after onset of compression. Using this using these data, using a chi-square model, a sample size of 250 to 300 patients equally divided between two groups, is necessary to achieve a 90% power with an alpha editor of 0.05. Expecting a 10% crossover rate will be accommodated a sample size of 200 patients will be needed. After randomizing 200 patients, an interim analysis will be performed. If event rates are low, the sample-size will be increased to 350 patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Radial Artery Injury at Wrist and Hand Level

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized comparison of patent hemostasis achievement with single bladder radial artery compression device with a dual-bladder ulnar compression capable radial artery compression device.
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: TR Band Arm

Patients will receive hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied using "Patent hemostasis protocol" to achieve full hemostasis.

Group Type PLACEBO_COMPARATOR

VasoBand

Intervention Type DEVICE

Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression

Group 2: Vaso-band Arm

Patients will receive Vaso-band (VasoInnovations, Inc, USA), applied with ulnar balloon inflated with 15 ml of air, and the radial balloon inflated after the sheath is removed, to apply optimal pressure for obtaining full hemostasis. Ulnar balloon will be deflated after 60 minutes of radial artery hemostatic compression.

Group Type ACTIVE_COMPARATOR

VasoBand

Intervention Type DEVICE

Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VasoBand

Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients referred for cardiac catheterization undergoing transradial access

Exclusion Criteria

* Previous ipsilateral radial artery cannulation, oral systemic anticoagulation therapy, thrombolytic therapy in the previous 7 days.
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Total Cardiovascular Solutions

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tejas M Patel, MD

Role: PRINCIPAL_INVESTIGATOR

Apex Heart Institute, Ahmedabad, India

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Apex Heart Institute

Ahmedabad, Gujarat, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A98

Identifier Type: -

Identifier Source: org_study_id